Project Details
Description
PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, partially owing to lack of effective
biomarkers and/or screening strategies. The 5-year survival of patients with localized PDAC is 39% compared
to 3% in patients diagnosed with metastatic disease, which indicates that detecting PDAC at early stage
positively impacts survival. A centrally curated/managed multi-institution biospecimen resource containing
prospectively collected, well-annotated biospecimens representing clinically relevant, diverse PDAC screening
populations is desperately needed. The overall goal of the Pancreatic Cancer Detection Consortium (PCDC)
Management and Data Coordinating Center (MDCU) is to facilitate the PCDC’s role in developing and utilizing
high quality, well annotated samples for PDAC biomarker discovery, triage, pre-validation, and validation. The
PCDC consortium is composed of multiple U01 Research Units (RU) and the MDCU, with NCI cooperation and
central biospecimen storage at the NCI Frederick Central Repository. We will leverage our expertise and
knowledge gained during the previous grant cycle to reinforce existing and new PCDC initiatives through
expanded coordination, and strengthening the infrastructure to support management of the PCDC Reference
Sets and Signature Protocols. Our Specific Aims are 1) To provide outstanding and timely administrative
coordination and logistical support for the Pancreatic Cancer Detection Consortium. 2) To strategically plan,
coordinate and implement the development of a well-annotated, uniformly collected and managed central PCDC
biorepository and database. 3) To provide the highest quality biostatistical leadership of PCDC collaborative
experimental design, study conduct, and analysis, and to provide biostatistical consultation to PCDC RUs. The
strengths of the MDCU are the breadth and depth of knowledge and understanding of PDAC provided by MDCU
personnel who will innovatively apply time tested infrastructure tools and strategies to consortium management,
and our vast experience in enhancing the scientific needs of PCDC collaborative research. Our multidisciplinary
team is committed to continue its leadership and contribution to the PCDC organization to advance the early
detection of pancreatic cancer.
Status | Active |
---|---|
Effective start/end date | 9/1/22 → 8/31/24 |
Funding
- National Cancer Institute: $646,653.00
- National Cancer Institute: $659,848.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.